Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.150
+0.020 (0.94%)
At close: May 1, 2026, 4:00 PM EDT
2.148
-0.002 (-0.11%)
After-hours: May 1, 2026, 7:59 PM EDT
Allogene Therapeutics Employees
As of December 31, 2025, Allogene Therapeutics had 152 total employees, including 150 full-time and 2 part-time employees. The number of employees decreased by 77 or -33.62% compared to the previous year.
Employees
152
Change (1Y)
-77
Growth (1Y)
-33.62%
Revenue / Employee
n/a
Profits / Employee
-$1,255,829
Market Cap
739.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 152 | -77 | -33.62% | 150 | 2 |
| Dec 31, 2024 | 229 | -4 | -1.72% | 226 | 3 |
| Dec 31, 2023 | 233 | -128 | -35.46% | 232 | 1 |
| Dec 31, 2022 | 361 | 51 | 16.45% | 359 | 2 |
| Sep 30, 2022 | 356 | 55 | 18.27% | 356 | 0 |
| Jun 30, 2022 | 344 | 59 | 20.70% | 344 | 0 |
| Mar 31, 2022 | 334 | 58 | 21.01% | 334 | 0 |
| Dec 31, 2021 | 310 | 45 | 16.98% | 308 | 2 |
| Sep 30, 2021 | 301 | 37 | 14.02% | 301 | 0 |
| Jun 30, 2021 | 285 | 49 | 20.76% | 285 | 0 |
| Mar 31, 2021 | 276 | 61 | 28.37% | 276 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Kura Oncology | 260 |
| Absci | 140 |
| Alpha Tau Medical | 121 |
| Solid Biosciences | 121 |
| Lexicon Pharmaceuticals | 81 |
| Vor Biopharma | 76 |
| Forte Biosciences | 19 |
ALLO News
- 12 days ago - Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewsWire
- 13 days ago - Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - GlobeNewsWire
- 16 days ago - Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - GlobeNewsWire
- 18 days ago - Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 19 days ago - Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - GlobeNewsWire
- 20 days ago - Allogene Therapeutics Transcript: Study result - Transcripts
- 20 days ago - Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Business Wire